Lung Cancer Trials Ask AI to find trials
CompletedPhase 1 / Phase 2NCT05002270
Official study title

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Study summary

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedJAB-21822 (KRAS G12C inhibitor) and JAB-21822 (KRAS G12C inhibitor)

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 13, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Jacobio Pharmaceuticals Co., Ltd.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Interventions being studied
Drug: JAB-21822 (KRAS G12C inhibitor); Drug: JAB-21822 (KRAS G12C inhibitor); Drug: JAB-21822 (KRAS G12C inhibitor); Drug: Cetuximab (EGFR inhibitor)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
KRAS→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants must be able to provide an archived tumor sample
  • Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
  • Must have received at least 1 prior standard therapy
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Must have adequate organ function
  • Must be able to swallow and retain orally administered medication
Reasons someone may not be able to joinExclusion criteria
  • Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
  • Active infection requiring systemic treatment within 7 days
  • Active HBV or HCV
  • Any severe and/or uncontrolled medical conditions
  • LVEF ≤50% assessed by ECHO or QTcF
  • QT interval \>470 msec
  • Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo ClincPhoenix, Arizona
  • Mayo ClincScottsdale, Arizona
  • Mayo ClincJacksonville, Florida
  • University of UtahSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 13, 2026. Always confirm current availability with the study team.

View original record ↗